What is Leerink Partnrs' Forecast for CRBU FY2029 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2029 earnings per share estimates for Caribou Biosciences in a research report issued to clients and investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of $0.26 for the year, down from their prior forecast of $0.28. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million.

Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Wednesday, March 19th. Bank of America dropped their price objective on Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences currently has an average rating of "Buy" and an average target price of $10.33.

Caribou Biosciences Price Performance

Shares of Caribou Biosciences stock traded up $0.00 during trading on Thursday, hitting $0.80. 414,431 shares of the company were exchanged, compared to its average volume of 1,558,645. The firm has a market capitalization of $74.40 million, a P/E ratio of -0.48 and a beta of 2.36. The firm's fifty day moving average price is $1.02 and its 200 day moving average price is $1.56. Caribou Biosciences has a 1-year low of $0.66 and a 1-year high of $4.21.

Institutional Investors Weigh In On Caribou Biosciences

Several institutional investors have recently bought and sold shares of CRBU. Barclays PLC lifted its position in Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company's stock worth $255,000 after buying an additional 71,463 shares in the last quarter. Geode Capital Management LLC raised its holdings in Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company's stock worth $3,980,000 after acquiring an additional 124,782 shares in the last quarter. Green Alpha Advisors LLC raised its holdings in Caribou Biosciences by 75.4% during the fourth quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company's stock worth $288,000 after acquiring an additional 77,840 shares in the last quarter. Thrive Wealth Management LLC acquired a new position in Caribou Biosciences during the fourth quarter valued at approximately $51,000. Finally, Milestone Asset Management LLC grew its stake in Caribou Biosciences by 5.6% in the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company's stock valued at $260,000 after purchasing an additional 8,662 shares in the last quarter. Institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.